Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human NI006 in ATTR cardiomyopathy
NL-OMON52809Phase 1Active, not recruiting
- Sponsor
- Neurimmune
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cliramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM) (3 arms), sponsored by Neurimmune. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 5 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
cliramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NL-OMON52809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52809.